EFTUD2: A 116 kDa U5 Small Nuclear Ribonucleoprotein Component as a Drug Target or Biomarker

Target Name: EFTUD2

NCBI ID: G9343

EFTUD2

EFTUD2: A 116 kDa U5 Small Nuclear Ribonucleoprotein Component as a Drug Target or Biomarker

Introduction

The small nuclear ribonucleoprotein (SNRNP) complex is a key regulator of gene expression and DNA replication in various organisms, including humans. The U5 is a subclass of SNRNP that contains a unique 116 kDa protein component (EFTUD2) that has been identified as a potential drug target or biomarker. In this article, we will provide an overview of EFTUD2, its function in the SNRNP complex, and its potential as a drug target or biomarker.

Function of EFTUD2 in the SNRNP Complex

The SNRNP complex is a protein-DNA complex that plays a crucial role in regulating gene expression and DNA replication. The complex consists of various subunits, including the U5 subunit that contains the 116 kDa protein component (EFTUD2) and the U1 subunit that contains the core RNA domain. The U5 subunit is a key regulator of DNA replication, and it has been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and chromatin remodeling.

In addition to its role in regulating DNA replication, EFTUD2 has also been shown to play a key role in the regulation of gene expression. Studies have shown that EFTUD2 can interact with various RNA-binding proteins (RBP), including CBP, to regulate the translation of specific genes. This interaction between EFTUD2 and RBP highlights the potential of EFTUD2 as a drug target or biomarker.

Potential Applications of EFTUD2 as a Drug Target

The identification of EFTUD2 as a potential drug target has significant implications for the development of new therapeutics for various diseases. EFTUD2 has been shown to play a role in the regulation of cellular processes that are associated with the development of various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One potential mechanism by which EFTUD2 may contribute to the development of cancer is its role in the regulation of cell growth and apoptosis. EFTUD2 has been shown to play a role in the regulation of cell cycle progression, and it has been shown to interact with various cellular signaling pathways that are involved in cell growth and apoptosis. Therefore, inhibiting the activity of EFTUD2 may be a potential strategy for the development of anti-cancer therapeutics.

In addition to its potential role in cancer, EFTUD2 may also be a potential target for neurodegenerative diseases. EFTUD2 has been shown to play a role in the regulation of neurotransmitter release and synaptic plasticity, which are important for the development and maintenance of neural circuits. Therefore, inhibiting the activity of EFTUD2 may be a potential strategy for the development of neurodegenerative disease therapies.

Potential Applications of EFTUD2 as a Biomarker

The identification of EFTUD2 as a potential drug target or biomarker has significant implications for the development of new diagnostic tools and therapeutic approaches. EFTUD2 has been shown to play a role in the regulation of various cellular processes, including gene expression and DNA replication. Therefore, the measurement of EFTUD2 levels in various biological samples, such as urine, blood, and tissue, may be a potential biomarker for the diagnosis and prognosis of various diseases.

In addition to its potential use as a drug target or biomarker, EFTUD2 may also be a useful tool for the study of disease mechanisms. The regulation of SNRNP activity by EFTUD2 is a complex process that involves the interplay of multiple proteins, including EFTUD2 itself, CBP, and RBP. Therefore, studying the mechanisms underlying

Protein Name: Elongation Factor Tu GTP Binding Domain Containing 2

Functions: Required for pre-mRNA splicing as component of the spliceosome, including pre-catalytic, catalytic and post-catalytic spliceosomal complexes (PubMed:28502770, PubMed:28781166, PubMed:28076346, PubMed:29361316, PubMed:30315277, PubMed:29360106, PubMed:29301961, PubMed:30705154). Component of the U5 snRNP and the U4/U6-U5 tri-snRNP complex, a building block of the spliceosome (PubMed:16723661). As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable)

The "EFTUD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EFTUD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets